Introduction Apixaban is a direct oral anticoagulant (DOAC) used to prevent and treat thrombosis. It is specifically indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of venous thromboembolism (VTE), and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Its predictable pharmacokinetics and oral administration make it a widely used alternative … Read more
Introduction Empagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting urinary glucose excretion. It also provides cardiovascular and renal protective benefits, and is approved for type 2 diabetes mellitus, heart failure, and chronic kidney disease. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, taken once daily Bioavailability ~78% … Read more
Introduction GLP-1 receptor agonists are a class of antidiabetic drugs that mimic the action of glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances insulin secretion in response to meals. These agents are used primarily in the treatment of type 2 diabetes mellitus and obesity. Their unique ability to improve glycemic control without causing significant hypoglycemia, … Read more
Introduction Carbidopa–Levodopa is a cornerstone therapy in the management of Parkinson’s disease. Levodopa serves as a precursor to dopamine, replenishing depleted levels in the brain, while carbidopa prevents premature peripheral metabolism of levodopa, ensuring its availability in the central nervous system. Together, they effectively improve motor symptoms such as bradykinesia, rigidity, and tremor. Step-by-Step Mechanism … Read more
Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone secreted from the L-cells of the distal ileum and colon in response to food intake. It plays a critical role in regulating glucose homeostasis and energy balance. GLP-1 acts through specific receptors found in the pancreas, gastrointestinal tract, and central nervous system to modulate insulin secretion, … Read more
Introduction Midodrine is a prodrug used in the treatment of symptomatic orthostatic hypotension. It works by increasing vascular tone through selective stimulation of alpha-1 adrenergic receptors after being metabolized into its active form, desglymidodrine. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral Bioavailability Approximately 93% Active Form Desglymidodrine Tmax 1–2 hours Half-life 3–4 … Read more
Introduction Vedolizumab is a humanized IgG1 monoclonal antibody used for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. It selectively targets the gastrointestinal immune system, offering gut-specific immunomodulation with minimal systemic immunosuppression. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Bioavailability Not applicable (IV administration) Half-life ~25.5 days Volume … Read more
Introduction Aripiprazole is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, major depressive disorder (as adjunct), irritability in autism, and Tourette’s syndrome. Its unique action as a dopamine D₂ partial agonist, along with effects on serotonin receptors, sets it apart from other agents, providing antipsychotic efficacy with a lower risk of certain side effects. … Read more
Introduction Infliximab is a chimeric (murine-human) IgG1 monoclonal antibody that targets tumor necrosis factor‑α (TNF‑α). It is used to treat a range of autoimmune and inflammatory disorders, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, and plaque psoriasis. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion … Read more
Introduction Dapagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor, used to treat type 2 diabetes mellitus (T2DM). Additionally, it offers benefits in heart failure and chronic kidney disease, independent of its glucose-lowering effects. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, once daily Bioavailability ~78% Protein Binding ~91% Metabolism Glucuronidation (UGT1A9) Half-life … Read more
